Official Title
Expanded Access to Venetoclax
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Status
Available
EA Type
Individual Patients
Conditions
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis
Plasma Cell Leukemia
Interventions

Drug: Venetoclax

Venetoclax will be administered orally.
Other Name: Array

Eligibility Criteria

Inclusion Criteria:

- The participant must not be eligible for a venetoclax clinical trial.

- Pediatric participants may be evaluated on a case by case basis.

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Contacts

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

Investigators

ABBVIE INC., Study Director
AbbVie

Sponsors / Collaborators
AbbVie
NCT Number
NCT03123029
Keywords
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Leukemia
Multiple Myeloma
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Plasma Cell
Amyloidosis
Venetoclax